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Abstract
An attenuated line of Leishmania infantum (L. infantum H-line) has been established by culturing promastigotes in vitro
under gentamicin pressure. A vaccine trial was conducted using 103 naive dogs from a leishmaniosis non-endemic area (55
vaccinated and 48 unvaccinated) brought into an endemic area of southeast Iran. No local and/or general indications of
disease were observed in the vaccinated dogs immediately after vaccination. The efficacy of the vaccine was evaluated after
24 months (4 sandfly transmission seasons) by serological, parasitological analyses and clinical examination. In western blot
analysis of antibodies to L. infantum antigens, sera from 10 out of 31 (32.2%) unvaccinated dogs, but none of the sera from
vaccinated dogs which were seropositive at .100, recognized the 21 kDa antigen of L. infantum wild-type (WT). Nine out of
31 (29%) unvaccinated dogs, but none of vaccinated dogs, were positive for the presence of Leishmania DNA. One out of 46
(2.2%) vaccinated dogs and 9 out of 31 (29%) unvaccinated dogs developed clinical signs of disease. These results suggest
that gentamicin-attenuated L. infantum induced a significant and strong protective effect against canine visceral
leishmaniosis in the endemic area.
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Introduction
Leishmania infantum (L. infantum) is a causative agent of visceral
leishmaniasis (VL), which is a severe and frequently lethal
protozoan disease of humans and dogs. Canine visceral leishman-
iosis (CVL) is widely distributed in large areas of Europe, South
America, the Middle-East, Central Asia, China, and Africa,
particularly in the countries of the Mediterranean Basin [1,2]. In
Iran, at least seven endemic foci in dogs have been identified
including the Baft district in the southeast of the country where
there is a high seroprevalence in domestic dogs [3]. Dogs are the
principal reservoir of L. infantum and can be an important threat to
public health. Control of the disease in dogs has been shown to
reduce the human incidence [4,5]. Although there have been a
number of vaccine trials, there is currently no effective and
completely safe vaccine against any form of leishmaniasis. A
successful vaccine against Leishmania is most likely to be either an
attenuated line or a subunit vaccine based on antigens with
demonstrable protective function [6,7]. Subunit and attenuated
vaccines can be highly effective and induces protection against
pathogen [8,9,10]. We previously reported that a cultured
attenuated line of L. infantum, identified as L. infantum H-line, was
selected by culturing promastigotes in vitro under pressure of
gentamicin [11]. Gentamicin, which has frequently been added to
cultures of Leishmania to prevent bacterial contamination [12,13], is
an aminoglycoside that interacts with RNA in prokaryotic cells
[14]. The precise mechanism of bactericidal activity of aminogly-
cosides is not fully understood, but some hypotheses include
disruption of ribosomal activity by breaking up polysomes,
misreading of mRNA during protein synthesis and production of
abnormal or nonfunctional proteins. Comparative proteomics
profiling of the attenuated line identified key changes in parasite
thiol-redox metabolism [15]. Thiol-redox metabolism is crucial for
Leishmania which is exposed to an oxidative burst when they
encounter their mammalian macrophage host cell [16]. L. infantum
H-line is more susceptible to oxidative stress, and thus a change in
thiol-redox metabolism in this line may explain its loss of virulence
[15]. L. infantum H-line invaded but was unable to survive within
bone marrow derived macrophages of BALB/c mice in vitro [11].
Moreover, the attenuated line failed to spread to, and within, the
visceral organs of BALB/c mice and dogs over a 12 week
observation period [17]. Immunohistochemical investigation
showed no parasites in the popliteal lymph node (PLN) of
immunized dogs whereas there were parasites in the PLN of 60%
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of dogs infected with L. infantum WT [18]. No clinical signs and
histopathological abnormalities were found in the dogs immunized
with the attenuated line of parasite over 2 years post-immunization
[17,19]. Dogs immunized with the attenuated line parasites
elicited a Th1 response and were protected against experimental
CVL [19]. We previously reported that Western blot analysis of
antibodies to the 21 kDa antigens of L. infantum H-line and WT
might be a useful technique for distinguishing between dogs
vaccinated with L. infantum H-line and dogs naturally infected with
L. infantum WT in epidemiologic studies [20].
In the present study, for the first time, we show the impact of L.
infantum H-line vaccine against natural infection in dogs in a highly
endemic area of Iran over a 24 month follow-up.
Materials and Methods
Parasites
Promastigotes of L. infantum JPCM5 (MCAN/ES/98/LIM-
877), were cultivated in complete haemoflagellate minimal
essential medium (HOMEM) (GIBCO) supplemented with 10%
(vol/vol) heat-inactivated fetal calf serum (HI-FCS) (Labtech
International). L. infantum H-line was generated in the same
medium supplemented with 10% (vol/vol) HI-FCS and gentami-
cin at 20 mg/ml (Sigma) [11]. Stationary phase promastigotes of
the attenuated line were harvested after 48 subpassages and a
suspension at a concentration of 56108 cells/ml in PBS was
prepared.
Study site
The field study was conducted in 3 villages, Dehsard,
Khosrowabad and Dehsarar of Baft County (56.2147uE,
28.2727uN), Kerman Province, in the southeast of Iran (Fig. 1a).
The area has a desert climate and the total annual rainfall is
309 mm with a minimum of 3 mm in July and maximum of
120.9 mm in April. The minimum mean monthly relative
humidity is 26% (June) and the maximum is 56% (January).
Initially, 77 household dogs were examined for clinical signs of the
disease and tested for the presence of specific anti-Leishmania
antibody by an immunofluorescence assay (IFA).
Ethics statement
A vaccine trial was conducted on 103 dogs (55 vaccinated and
48 unvaccinated). The protocol for vaccination of the dogs had
been reviewed and approved by the Medical Ethics and Animal
and Use Care Committee of the Kerman Medical University
(study protocol number KA/89/15), in accordance with the Guide
for the Care and Use of Laboratory Animals Eighth Edition. The
animals were kept under typical local conditions of food and
housing and sampled with the owners’ consent. All dogs with
clinical signs of disease were sacrificed to avoid unnecessary
suffering.
Study design and animal
On the basis of the rate of seropositivity detected in the 77 dogs
tested (see above), and to anticipate a number of dogs being lost
during the follow-up period of 24 months, a total 103 dogs were
used in this study. At follow-up prior of starting, we expected 60%
seropositive in the unvaccinated group and 20% seropositive in
vaccinated group, with a confidence level of 0.95 and power of 0.9,
and ratio of 1.29 sample size (i.e. n2/n1 equivalent to 45/35). This
estimated a sample of 31 in unvaccinated group and 40 in
vaccinated group. Ten unvaccinated dogs and 13 vaccinated dogs
were considered to lose at follow-up prior in this study. One
hundred and three healthy male German shepherd cross dogs
from non-endemic areas (Kerman city 225 Km northwest of
Dehsard) (Fig. 1b) between 6–18 months old were used. All of the
animals were negative for presence of leishmanial DNA and serum
specific anti-Leishmania IgG antibody. The dogs had previously
been vaccinated against canine parvovirus and rabies and were
also treated with the anthelmintic drugs praziquantel and pyrantel.
The weight and age were recorded for each dog and they were
randomly divided into 2 groups (55 dogs in vaccinated group and
48 dogs in unvaccinated group). The dogs in the vaccinated group
were injected subcutaneously (s.c) with 100 ml of the suspension of
stationary phase promastigotes in the foreleg of the animals. The
unvaccinated dogs were injected subcutaneously with 100 ml of
PBS also in the foreleg. The dogs were transferred into the
endemic area over a period of 1.5 months before June 2010 and
re-homed at households within the endemic area. Information
about the risk of the procedures was given to persons who became
owners of dogs. We included vaccinated and control dogs in each
house whenever possible, in order to match their degree of
exposure to natural infection.
Follow-up
The dogs were followed up over 24 months, from June 2010 to
cover four sandfly seasons, which occur in June and September in
the endemic areas of the southeast of Iran [21]. The efficacy of the
vaccine was evaluated by clinical examination and serological and
parasitological analyses. Active disease surveillance measures were
implemented in each of the study villages. A trained worker was
located in the Health House in the village, and together with our
team had responsibility for disease monitoring. The follow-up was
performed at 3, 6, 9, 12, 18, 20 and 24 months after starting trial.
The peripheral blood samples were taken for complete blood cells
(CBC) count and biochemical parameters including serum total
protein, serum albumin and serum globulin. The clinical signs of
disease were classified according to a modified version of leishvet
guidelines as described previously [22]. Briefly, Stage I, Mild
disease, animals exhibiting peripheral lymphadenomegaly or
papular dermatitis, creatinine ,1.4 mg/dl, non-proteinuric,
negative to low levels of antibody. Stage II, Moderate disease,
animals, which apart from the signs listed in stage I, may exhibit
diffuse or symmetrical cutaneous alterations (exfoliative dermati-
tis/onychogryphosis, ulcerations (planum nasale, footpads, bony
prominences, mucocutaneous junctions), anorexia, weight loss,
fever, and epistaxis, mild non-regenerative anemia, hyperglobu-
linemia, hypoalbuminemia, normal renal profile, creatinine ,
Author Summary
A 24 month vaccine trial was conducted using 103
leishmania free dogs in an area of southeast Iran endemic
for visceral leishmaniosis. The dogs were vaccinated with
gentamicin-attenuated line of Leishmania infantum. No
local and/or general indications of disease were observed
in the vaccinated dogs immediately after vaccination with
an attenuated line of Leishmania infantum. Nine out of 31
(29%) unvaccinated dogs, but none of those vaccinated,
were positive for presence of Leishmania DNA by PCR. In
western blots, sera from 10 out of 31 (32.2%) unvaccinated
dogs, but none of the sera from vaccinated dogs,
recognized the 21 kDa antigen of Leishmania infantum
wild-type. One out of 46 (2.2%) vaccinated dogs and 9 out
of 31 (29%) unvaccinated dogs developed clinical signs of
disease. The attenuated Leishmania infantum induced a
significant and strong protective effect against Leishmania
infantum infection in the field.
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1.4 mg/dl, low to high levels of antibody. Stage III, Severe disease,
animals which apart from the signs listed in stages I and II, may
exhibit signs originating from immune-complex lesions such as
vasculitis arthritis and glomerulonephritis, chronic kidney disease,
creatinine 1.4–2 mg/dl, medium to high levels of antibody. Stage
IV, Very severe disease, animals which, apart from the signs listed
in stages I, II and III, may exhibit signs pulmonary thromboem-
bolism, or nephrotic syndrome and end stage renal disease
(creatinine .5 mg/dl) with medium to high levels of antibody.
Twenty six out of 103 (25.2%) dogs left or died from a disease
unrelated to leishmaniosis over the 24 month period follow-up. All
unvaccinated dogs were sacrificed by intravenous injection of
thiopental sodium 33% (5 ml/kg) [23] at the end of the study. Five
ml of peripheral blood were taken from the foreleg vein of each
dog in EDTA for isolating parasite DNA for PCR test, and 2 ml
for separation of sera for IFA and Western blotting test. The
samples were stored at 220uC.
Detection specific anti-Leishmania total IgG, IgG1, and
IgG2 antibodies
Specific anti-Leishmania total IgG antibody was measured by
IFA as described previously [24]. Briefly, slides were coated
with washed promastigotes of L. infantum WT and air dried.
Slides were incubated with twofold dilutions of the test samples
in humid moist conditions for 60 min at 37uC. Excess antibody
was washed off the slides and bound antibody was detected
using fluorescein isothiocyanate (FIT) conjugated sheep anti-
dog IgG (Sigma), diluted at 1:400 in PBS-0.01% Evans blue.
Specific anti-Leishmania IgG1 and IgG2a antibodies were
measured by ELISA as described previously [19]. Briefly,
serum was prepared from the clotted blood of dogs at 20-
month post follow-up and stored at 220uC. Each well of flat-
bottom microtitre plates was coated with 1 mg of soluble
Leishmania antigen in 0.1 M carbonate buffer pH 9.6 and
incubated at 4uC overnight. Following 3 washes in PBS
(pH 7.4) containing 0.05% Tween-20, the plates were blocked
with 200 ml of blocking buffer (1% BSA in PBS), and
incubated at 37uC for 1 h. After 3 washes, 100 ml of serially
diluted serum sample (1:100 starting dilution in PBS/BSA 1%)
was added to the wells and incubated for 2 h at 37uC. Bound
antibodies were detected by 50 ml/well goat anti-dog IgG1
conjugated to HRP at 1:500 dilution and for detection of IgG2,
50 ml/well sheep anti-dog IgG2 conjugated to HRP at 1:5000
dilution (Bethyl Laboratories, Montgomery, TX, USA). The
plates were incubated at 37uC for 1 h and subsequently
washed 6 times. One-hundred ml of TMB substrate were added
to each well. The reaction was stopped after 15 min incubation
at room temperature using H2SO4 (0.5 M) (50 ml). Absorbanc-
es were measured at 405 nm on an ELISA reader.
Western blotting
The Western blot technique was applied as described
previously [25]. Briefly, stationary phase promastigotes of L
infantum H-line or wild-type parasite (16107 cells per lane) were
washed with ice-cold PBS three times, and disrupted by
sonication. An equal volume of sample buffer [0.1 M Tris
(Merck), 12% sodium dodecyl sulfate (Merck), 10% glycerol
(Merck), 5% b-mercaptoethanol (Merck), 0.1% bromophenol
blue, pH 8.0] was mixed and the solution denatured at 95uC for
5 min. Promastigote lysates were fractioned individually on a
12% SDS-PAGE gel and subsequently transferred onto a
nitrocellulose membrane (Sigma-Aldrich). The blots were indi-
vidually incubated with 1:50 diluted sera in PBS containing 3%
skimmed milk at room temperature for 18 h. The blots were
incubated with 1:10000 diluted goat anti-dog IgG-heavy and
light chains antibody horseradish peroxidase (HRP) conjugated
Figure 1. Maps representing (a) the geographical locations where this study was carried out, in 3 villages of Baft County, Kerman
Province, in the southeast of Iran. (b) Kerman city 225 Km of northwest of Dehsard, the leishmaniosis non-endemic area. Healthy German
shepherd cross dogs obtained from Kerman city and brought into Dehsard, the leishmaniosis endemic areas.
doi:10.1371/journal.pntd.0002757.g001
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(Bethyl Lab. Inc) in PBS containing 5% skimmed milk at room
for 2 h. The blots were washed as above, incubated with ECL
Plus chemiluminescent substrate (GE Healthcare), and exposed
to X-ray film.
DNA extraction and diagnostic PCR
The possible presence of leishmanial DNA was assayed in
peripheral blood and PLN necropsy. DNA was extracted
(Promega, Columbus, OH, USA), according to the manufacturer’s
instructions and stored at220uC until use. PCR amplification was
carried out in 50 ml reaction volumes using 0.5 pmol of the
kinetoplastid-specific primers K13A (59-GTGGGGGAGGGG-
CGTTCT-39) and K13B (59-ATTTTACACCAACCCCCA-
GTT-39) [26]. The amplification products were analysed by
1.5% agarose gel and visualized under UV light. A positive control
containing genomic DNA of Leishmania-infected dog and negative
control without template DNA were included.
Report of VL cases from vaccine trial areas
VL cases were monitored from the records of each of the
pediatric wards of Afzelipour Medical Centre at Kerman
University of Medical Sciences. As VL cases might occasionally
be referred to other hospitals, further information on VL cases
were obtained from Centre for Disease Control and Prevention in
Kerman Medical University.
Statistical analysis
Statistical analyses were performed with statistical package
EpiTool (available at http://epitools.ausvet.com.au) to determine
the number of animals in the vaccine trial. For quantitative data,
Student’s t-test was used to calculate differences the levels of IgG
between two groups. Comparison between the levels of IgG1 and
IgG2 antibodies was performed using Paired sample t-test. Chi-
square test was used to examine the relationship between the
number of dogs which IFA titers of IgG antibody were at .1:100
between 2 groups. Fisher’s exact test was used to calculate
difference leishmanial DNA between 2 groups. Data are expressed
as the mean 6 standard deviation mean (SDM) for each group.
Differences were considered significant when P,0.05.
Results
Screening of household dogs before vaccine trial
Seventy seven household dogs, living in the endemic areas, were
examined for clinical signs of the disease and tested for presence of
specific anti-Leishmania IgG antibody. Specific anti-Leishmania
antibody by IFA was found in 31 out of 77 (40.2%) of the
householder dogs ($1:100). Sixty two out of 77 (80.5%) animals
were asymptomatic.
Follow-up
The efficacy of the vaccine was evaluated after 4 sandfly
transmission cycles by clinical examination, and serological and
parasitological analyses. A vaccine trial was conducted on 103
dogs (55 vaccinated and 48 unvaccinated). No local indications
including swelling, and pain at the injection site and no general
indications of disease including anorexia, apathy, vomiting and
diarrhoea were observed after the vaccine administration. Twenty
three dogs (9 vaccinated and 14 unvaccinated) (22.3%) left the
study after a change in residence or disappearance. Three
unvaccinated dogs (2.9), died. Two of these dogs had to be put
down because of accidental injury and one died from a disease
unrelated to leishmaniosis.
Specific anti-Leishmania total IgG, IgG1, and IgG2
antibodies
All vaccinated dogs gave positive titers of specific anti-Leishmania
antibodies whereas, all but 2 unvaccinated dogs were seronegative
over the 3 month follow-up (Fig. 2). Fluctuations of the mean levels
of antibody were observed in the sera of vaccinated dogs over the
20 month follow-up (Fig. 2) but did not rise. In contrast, the mean
levels of antibody increased in the sera of unvaccinated dogs over
the same period (Fig. 2). There was a significant difference
between mean levels of antibody in the sera of vaccinated and
unvaccinated dogs (P,0.001). The cut-off for which animals were
considered seropositive was established to be a positive IFA results
at serum dilutions of .1:100. As shown in Table 1, twelve out of
31 (38.7%) unvaccinated dogs and 2 out of 46 (4.3%) vaccinated
dogs were seropositive at .1:100. The rest of dogs, 19 out of 31
(61.2%) unvaccinated dogs and 44 out of 46 (95.7%) vaccinated
dogs were seropositive #1.100 over the 24 month follow-up. The
number of unvaccinated dogs which were seropositive at .1:100
was significantly higher than vaccinated dogs (P,0.0005). Specific
anti-Leishmania IgG1 and IgG2 antibodies were present in the sera
of dogs vaccinated with L. infantum H-line, predominantly of the
IgG2 subclass. In the sera of vaccinated dogs, the level of IgG1 was
significant lower than the level of IgG2 (P,0.001) whereas, the
level of IgG1 was significantly higher than the level of IgG2 in the
sera of unvaccinated dogs (P,0.05).
Western blot analysis
Two sera from vaccinated dogs which were seropositive at .
1:100, dogs V20 and V33, recognized the 21 kDa antigen of L.
infantum H-line but not of L. infantum WT (Fig. 3). Ten out of 31
(32.2%) unvaccinated dogs which were seropositive at .1:100
recognized the 21 kDa antigen of L. infantum WT, but not of L.
infantum H-line (Table 1). As shown in Table 1, sera from 2
unvaccinated dogs, C2 and C61 were seropositive at .1:100 but
did not recognize the 21 kDa antigen of both L. infantum H-line
and L. infantum WT. Sera from all dogs in both groups which were
seropositive at #1:100 did not recognize any antigens of L.
infantum H-line or wild-type parasites.
Clinical signs and leishmanial DNA analysis
The presence of leishmanial DNA and clinical signs of disease in
vaccinated and unvaccinated dogs after 4 sandfly seasons are
summarized in Table 1. No leishmanial DNA was found in the
vaccinated dogs. In contrast, 9 out of 31 (29%) unvaccinated dogs
were positive for the presence of leishmanial DNA over the 24
month period follow-up. As shown in Table 1, eight of 12 (66.7%)
unvaccinated dogs with high levels of antibody (.1:100) became
PCR positive. The number of unvaccinated dogs that were PCR
positive was significantly higher than that in the vaccinated dogs
(P,0.002). All but 1 vaccinated dogs, [(2.2%), remained free of
clinical abnormalities over the 24 months period of observation.
Among the unvaccinated dogs, 9 out of 31 [(29%), two dogs, C8
and C1 in stages II and III of clinical signs of disease, respectively],
presented one or more clinical signs of disease (Table 1).
Report of VL cases from vaccine trial area
No VL cases were referred to the Afzalipour Medical Centre or
recorded in the Centre for Disease Control and Prevention from
the area of study more than 3 years since June 2010.
Discussion
This is the first study to demonstrate efficacy of an attenuated L.
infantum vaccine against natural CVL in dogs in a highly endemic
Gentamicin-Attenuated Leishmania infantum Vaccine
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area. The progression of leishmaniosis in dogs is associated with
humoral response and depression of cellular immunity [27]. We
previously reported that L. infantum H-line induced a CD4+Th1
response which was characterized by the production of relatively
higher levels of IFN-c and lower levels of IL-10 compared with
those in the dogs infected with wild-type parasite [18,19]. In
contrast to L. infantum WT, the attenuated parasite was unable to
multiply and survive in the visceral organs of immunized dogs [17]
and remained localized in the skin at the site where the
promastigotes were injected. It has been reported that promasti-
gotes of L. infantum WT develop to amastigote forms in infected
macrophages at the site of inoculation and the infection may
spread, resulting in a systemic form [1]. Dissemination of the
parasite in the visceral organs of symptomatic dogs is the result of the
development of a non-protective Th2 response [28]. Subcutaneous
vaccination with the attenuated line in the foreleg of the dogs, an
area covered with hair, will prevent or significantly reduce the
likelihood of uptake of attenuated line parasites by sandflies, which
tend to feed only on areas of exposed skin. This observation
alleviates concerns about the possibility of reversion to virulence
by the attenuated line during passage through sandflies.
We reported subclasses of IgG in vaccinated dogs and
correlated higher IgG2 with protection provided by L. infantum
H-line [19]. In the present study, we found the level of IgG1
was significant lower than the level of IgG2 in the sera of
vaccinated dogs. It has been reported that specific anti
Lieshmania IgG1 in dogs is associated with the development of
disease, whereas IgG2 antibody is associated with asymptom-
atic infection [29].
The present study was carried out in 3 villages, in the district of
Dehsard, Baft County in the southeast of Iran highly endemic for
CVL [3,30,31]. In a preliminary study, we found that 40.2% of the
household dogs were seropositive for L. infantum (.1:100).
However, the prevalence of CVL in domestic dogs in this area
might be higher than 40.2%. It has been reported that 37% of
seronegative asymptomatic dogs from an endemic area were positive
by the PCR with skin tissue [32]. It is recognized that introducing
103 dogs into an area could disturb the ecological dynamics
between dogs, parasite and vectors. Householders whose dogs
were seronegative did not allow their dogs to be used in the study.
Thus dogs from a non-endemic area were brought in for the trial
and whenever possible each household included unvaccinated and
vaccinate dogs in order to equalize their degree of exposure to the
risk of natural infection. The seroposivity of unvaccinated dogs
was higher than that of household dogs, living in the area. It has
been reported that some dog breeds such as the German shepherd
are more susceptible to development of CVL [33,34].
In the unvaccinated group 12 out of 31 dogs (38.7%) dogs were
highly seropositive (.1:100) which 35.5% of them developed signs
of CVL over 24 months of period of monitoring. The specific anti-
Leishmania IgG antibody was raised in the sera of the dogs
vaccinated with L. infantum H-line [17,19]. We found that except 2
unvaccinated dogs, all sera from the vaccinated dogs and
unvaccinated dogs which were seropositive at .1:100 recognized
the 21 kDa antigens of L. infantum H-line or WT. It is in agreement
with another study that band of 21 kDa has the highest immuno-
reactivity and the most often recognized in the case of CVL [35].
In the present study we found sera from vaccinated dogs
Figure 2. Mean levels of specific anti-Leishmania total IgG antibody in the sera of vaccinated (¤) and unvaccinated dogs (&). The
dogs in the vaccinated group were injected with the L. infantum H-line and then transferred into the endemic area over a period of 1.5 months.
Antibodies were detected by IFA pre-vaccination and over a 20 month period follow-up. The number of vaccinated dogs (n1) and unvaccinated dogs
(n2) were assayed at each individual time point. After 1.5 months transferred into the endemic area. Each point represents average 6 SDM.
doi:10.1371/journal.pntd.0002757.g002
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recognized the 21 kDa antigen of L. infantum H-line whereas, sera
from unvaccinated dogs, which were natural infected with
L. infantum WT recognized the 21 kDa antigens of L. infantum
WT (Table 1). This observation is in agreement with our previous
study that Western blot analysis of antibodies to the 21 kDa
antigens of L. infantum H-line and WT is very useful method for
distinguishing between dogs vaccinated with L. infantum H-line and
dogs experimentally infected with L. infantum WT [20]. We found
that sera from 2 unvaccinated dogs, C2 and C61, which were
seropositive at .1:100 did not recognize any antigens of L.
infantum H-line or L. infantum WT (Table 1). It has been reported
that the sensitivity and specificity of Western blotting is greater
than IFA for diagnosis of CVL in dogs [25]. IFA cross-reaction
antibody between L. infantum and other diseases such as Ehrlichias
canis (E. canis) and Babesia canis and also some kind of clinical signs
of disease might be possible [36,37,38]. Moreover, E. canis
infection might induce immunosuppression [39] and therefore
the immune system is not able to develop the protective immunity
induced by the attenuated line and the vaccinated animal is not
immune to natural challenge. This observation may be useful to
explain the sign of disease in 2 vaccinated dogs,V20 and V33, over
24 months period monitoring and suggests in the future, we need
to check for the presence of E. canis during vaccination with the
attenuated L. infantum.
A number of vaccines such as FLM, LiESAp-MDP have shown
a degree of effectiveness against experimental CVL in dogs
[40,41]. Our study is the first vaccine trial in dogs that might show
an impact of a vaccine and in reducing the occurrence of VL in
the local human population. It has been reported that human
seropositive (.1:800) in this area was 1.55% and approximately
half of 108 registered cases were from Baft [3]. No VL cases were
recorded from the area of study 3 years since these data were
collected. Impact of this vaccine on human population should be
confirmed in the further studies. The results presented clearly
demonstrated that a gentamicin-attenuated line L. infantum vaccine
induced a significant and strong protective effect against CVL in
Table 1. Clinical stages of disease, IFA titers of specific anti-Leishmania antibody, presence of leishmanial DNA in LN and western
blot analysis were evaluated in all dogs from both groups.
Group Animal code Clinical stage IFA titer PCR
Recognize 21 kDa antigen of
L. infantum WT
Vaccinated V20 * 1:400 2 2
dogs V33 - 1:400 2 2
Total 0/46 (0%) 2/46 (4.3%) 0/46 (0%) 0/46 (0%)
Control C2 - 1:400 2 2
dogs C5 II 1:800 + +
C9 III ** + +
C12 - 1:400 2 +
C16 - *** + 2
C27 II 1:800 + +
C28 I 1:400 2 +
C46 II 1:1600 + +
C48 II 1:1600 + +
C49 II 1:1600 + +
C52 II 1:1600 + +
C59 II 1:1600 + +
C61 - 1:400 2 2
Total 9/31(29%) 12/31(38.7%) 9/31(29%) 10/31(32.2%)
*: Moderate weight loss unrelated to leishmaniasis.
**: Dog was seropositive at 1:3200 and sacrificed at 19-month post follow-up.
***: Dog was seropositive at 1:100.
doi:10.1371/journal.pntd.0002757.t001
Figure 3. Western blot analysis of antibodies to L. infantum
antigens vaccinated dogs, V20 and V33, and unvaccinated
dogs infected naturally with L. infantum WT, C49. Sera of
vaccinated dogs recognized the 21 kDa antigen of L. infantum H-line
(H-line), but not of L. infantum WT (WT). Whereas, sera from some
unvaccinated dogs infected naturally with L. infantum WT, recognized
21 kDa of L. infantum WT, but not of L. infantum H-line. Stationary
phase of promastigotes (16107 cells per lane) were dissolved in sample
buffer and run on a 12% SDS-PAGE gel. Blot was incubated with goat
anti-dog IgG antibody HRP conjugated and then incubated with ECL
Plus chemiluminescent substrate.
doi:10.1371/journal.pntd.0002757.g003
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dog and holds considerable promise for vaccination of dogs against
CVL in the field.
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